APPLICATION PROCESS

Grant applications should be submitted by the department chairs, division chiefs, or fellowship directors of the academic institutions and must be received by Allergan Medical Affairs no later than Friday, May 29, 2009.

Application components

The application must include:

1. Information about the fellow’s institution and fellowship program.
2. How the funds will be used to advance research in glaucoma, corneal, or retinal diseases.
3. A summary of the research program and educational plan for the fellow’s research.

Only 1 application per academic institution may be submitted. Only 1 Horizon Grant will be granted per institution in a 2-year time frame. Applicants cannot have a familial relationship with a member of the Academic Advisory Board. Award recipients who recieved a Horizon Grant within the past 2 years are ineligible for 2009 consideration. Educational grants are subject to objective evaluation and are awarded to a limited number of applicants. Funding is not available for research conducted outside the United States. Research must be conducted by a US-based clinical fellow in a clinical setting.

SELECTION PROCESS

Grant applications will be reviewed by the Allergan Grant Review Committee with the assistance of the Horizon Academic Advisory Board, an independent advisory board made up of experts in the fields of glaucoma, cornea, and retina.* Applications will be reviewed and grants will be awarded based on the strength of the fellowship program, the clinical and research plan for the institution’s fellow, how the grant funds will be used, and activities the fellow will be engaged in while in the program. Grants will only be awarded to fellowship programs that conduct clinical research in the diagnosis or pharmacological treatment of glaucoma, corneal, and retinal diseases.

The Horizon Academic Advisory Board is composed of 3 advisors each in glaucoma, cornea, and retina. The advisors will each serve 2-year terms. Horizon Academic Advisory Board members do not participate in the evaluation of applications from their own institutions. Horizon Academic Advisory Board members serve in their individual capacities and any opinions/views expressed in connection with their service may not reflect the opinions/views of their employers or other affiliated institutions. Views expressed by board members are not sanctioned or endorsed by their employers or affiliated institutions.

*If appropriate applications are not received in a specific disease category, the grant money will not be awarded.

PROGRAM ADMINISTRATION/STIPULATIONS

Allergan Horizon Grants are educational grants paid to the institution. The grants will be distributed to the institution this summer. The institution is responsible for administering the funds in accordance with its prevailing procedures and policies, and the stated stipulations of this Allergan grant.

Use of funding: The Allergan Horizon Grant is intended primarily to support salary and research of the institutions’ fellows and shall not be used for overhead, indirect, or fringe costs. Use of award funds toward direct expenses necessary for the proper operation of the fellowship program is also acceptable. This funding is being provided solely for educational purposes. This grant is not intended, nor should it be construed as, a reward for past or incentive for future decisions regarding the prescription, use, purchase, or recommendation of Allergan products. Allergan expects recipients and their institutions to exercise their best and independent professional judgment regarding the care and treatment of individual patients.

Transferability, forfeiture, and termination: Should the institution anticipate changes in their fellow’s program circumstances or situation for reasons including, but not limited to, discontinuation of the program, Allergan must be notified promptly. If forfeiture, temporary suspension, or termination of the grant is desired or warranted by Allergan or the institution, a written agreement of the same shall be executed, terminating the agreement. Any unused grant funds must be returned to Allergan.